JP6518197B2 - バース症候群の予防または治療のための方法及び組成物 - Google Patents

バース症候群の予防または治療のための方法及び組成物 Download PDF

Info

Publication number
JP6518197B2
JP6518197B2 JP2015560377A JP2015560377A JP6518197B2 JP 6518197 B2 JP6518197 B2 JP 6518197B2 JP 2015560377 A JP2015560377 A JP 2015560377A JP 2015560377 A JP2015560377 A JP 2015560377A JP 6518197 B2 JP6518197 B2 JP 6518197B2
Authority
JP
Japan
Prior art keywords
subject
acid
taz1
peptide
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015560377A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016511259A5 (enExample
JP2016511259A (ja
Inventor
ディー トラヴィス ウィルソン
ディー トラヴィス ウィルソン
マーク バンバーガー
マーク バンバーガー
Original Assignee
ステルス バイオセラピューティックス コープ
ステルス バイオセラピューティックス コープ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステルス バイオセラピューティックス コープ, ステルス バイオセラピューティックス コープ filed Critical ステルス バイオセラピューティックス コープ
Publication of JP2016511259A publication Critical patent/JP2016511259A/ja
Publication of JP2016511259A5 publication Critical patent/JP2016511259A5/ja
Priority to JP2019080101A priority Critical patent/JP6918046B2/ja
Application granted granted Critical
Publication of JP6518197B2 publication Critical patent/JP6518197B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2015560377A 2013-03-01 2014-02-28 バース症候群の予防または治療のための方法及び組成物 Active JP6518197B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019080101A JP6918046B2 (ja) 2013-03-01 2019-04-19 バース症候群の予防または治療のための方法及び組成物

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361771642P 2013-03-01 2013-03-01
US201361771534P 2013-03-01 2013-03-01
US61/771,642 2013-03-01
US61/771,534 2013-03-01
US201361839753P 2013-06-26 2013-06-26
US61/839,753 2013-06-26
PCT/US2014/019622 WO2014134554A1 (en) 2013-03-01 2014-02-28 Methods and compositions for the prevention or treatment of barth syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019080101A Division JP6918046B2 (ja) 2013-03-01 2019-04-19 バース症候群の予防または治療のための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2016511259A JP2016511259A (ja) 2016-04-14
JP2016511259A5 JP2016511259A5 (enExample) 2017-04-06
JP6518197B2 true JP6518197B2 (ja) 2019-05-22

Family

ID=51428869

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015560377A Active JP6518197B2 (ja) 2013-03-01 2014-02-28 バース症候群の予防または治療のための方法及び組成物
JP2019080101A Active JP6918046B2 (ja) 2013-03-01 2019-04-19 バース症候群の予防または治療のための方法及び組成物
JP2021019903A Active JP7072692B2 (ja) 2013-03-01 2021-02-10 バース症候群の予防または治療のための方法及び組成物
JP2022077425A Active JP7381652B2 (ja) 2013-03-01 2022-05-10 バース症候群の予防または治療のための方法及び組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019080101A Active JP6918046B2 (ja) 2013-03-01 2019-04-19 バース症候群の予防または治療のための方法及び組成物
JP2021019903A Active JP7072692B2 (ja) 2013-03-01 2021-02-10 バース症候群の予防または治療のための方法及び組成物
JP2022077425A Active JP7381652B2 (ja) 2013-03-01 2022-05-10 バース症候群の予防または治療のための方法及び組成物

Country Status (9)

Country Link
US (6) US9687519B2 (enExample)
EP (2) EP3626252A1 (enExample)
JP (4) JP6518197B2 (enExample)
CN (3) CN115990242A (enExample)
CA (1) CA2916880C (enExample)
DK (1) DK2961420T3 (enExample)
ES (1) ES2750258T3 (enExample)
HU (1) HUE046924T2 (enExample)
WO (1) WO2014134554A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2858550A1 (en) * 2011-12-09 2013-06-13 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
EP3626252A1 (en) 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10793597B2 (en) 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US9550981B2 (en) 2014-01-22 2017-01-24 University Of Washington Modified tafazzin proteins and methods of making and using the same
US10086040B2 (en) 2014-12-12 2018-10-02 University Of Washington Methods for treating and preventing cardiomyopathy with a fusion protein of tafazzin and a cellular permeability peptide
WO2018104172A1 (en) 2016-12-06 2018-06-14 Centre National De La Recherche Scientifique (Cnrs) Compounds for treating barth syndrome
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
WO2020131283A1 (en) * 2018-12-18 2020-06-25 Stealth Biotherapeutics Corp. Analogs that target mitochondrial diseases

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
AU2002367469A1 (en) 2001-08-06 2003-09-22 Vanderbilt University Device and methods for measuring the response of at least one cell to a medium
BRPI0105509B8 (pt) 2001-11-05 2021-05-25 Univ Minas Gerais formulações do peptídeo angiotensina-(1-7) usando as ciclodextrinas, lipossomas e o polímero plga
SI2656854T1 (sl) 2003-02-04 2015-09-30 Cornell Research Foundation, Inc. Uporabe aromatsko-kationskega peptida
CN101440124B (zh) 2003-02-04 2012-07-18 科内尔研究基金会 用于防止线粒体通透性改变的方法
EP1597276A4 (en) * 2003-02-10 2006-11-29 Autogen Res Pty Ltd Therapeutic molecules
WO2005023274A1 (en) 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
CA3024434A1 (en) 2004-01-23 2005-08-11 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US8500720B2 (en) 2005-05-09 2013-08-06 Medtronic, Inc Method and apparatus for treatment of cardiac disorders
US20070265216A1 (en) * 2005-10-05 2007-11-15 Gross Richard W Enhanced medical treatment in diabetic cardiomyopathy
EP2012800A2 (en) 2006-04-18 2009-01-14 Cortendo Invest, AB Methods and compositions for treating barth syndrome, cardiomyopathy, mitochondrial diseases and other conditions
CA2688125A1 (en) 2007-05-02 2008-11-13 The Mclean Hospital Corporation Methods and compositions for mitochondrial replacement therapy
US20080318909A1 (en) * 2007-06-14 2008-12-25 Sparagna Genevieve C Use Of Linoleic Compounds Against Heart Failure
US20090143279A1 (en) 2007-06-15 2009-06-04 Vamsi Krishna Mootha Methods and compositions for treating metabolic disorders
CN107802821A (zh) 2008-02-26 2018-03-16 康奈尔大学 用于防止和治疗急性肾损伤的方法
WO2009149307A2 (en) 2008-06-04 2009-12-10 San Diego State University Research Foundation Compositions and methods for restoring mitochondrial electron transfer function
KR20130133103A (ko) 2008-08-07 2013-12-05 입센 파마 에스.에이.에스 Ｎ-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(ｇｉｐ)의 유사체
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
EP2419513A2 (en) 2009-04-17 2012-02-22 The Salk Institute For Biological Studies Regulation of aging by modulation of mitochondrial function
US20120046363A1 (en) 2009-05-11 2012-02-23 University Of Maryland, Baltimore Docosahexaenoic acid for the treatment of heart failure
CA2770688C (en) 2009-08-12 2018-06-05 Cornell University Methods for preventing or treating metabolic syndrome
SI3708178T1 (sl) * 2009-08-24 2024-01-31 Stealth Biotherapeutics Inc. Peptid za uporabo pri preprečevanju ali zdravljenju degeneracije makule
EP3603658B1 (en) 2009-10-05 2025-01-08 Cornell University Peptide for use in the treatment of heart failure resulting from hypertrophic cardiomyopathy
US8719939B2 (en) 2009-12-31 2014-05-06 Mcafee, Inc. Malware detection via reputation system
CA2797644A1 (en) 2009-12-31 2011-07-07 Edison Pharmaceuticals, Inc. Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
US20130195837A1 (en) 2009-12-31 2013-08-01 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
JP4643749B1 (ja) 2010-02-03 2011-03-02 昭和電工株式会社 表面被覆サーメット部材の耐酸化膜形成用の処理液
EP3332795A1 (en) 2010-02-26 2018-06-13 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP2808029A3 (en) * 2010-03-15 2015-04-01 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
JP2013532124A (ja) * 2010-05-03 2013-08-15 ステルス ペプチドズ インターナショナル インコーポレイテッド 芳香族系陽イオンペプチド及びその使用
US20130288985A1 (en) 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
WO2012019032A1 (en) 2010-08-06 2012-02-09 Ampere Life Sciences, Inc. Treatment of mitochondrial diseases with vitamin k
US20130345312A1 (en) 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
US9241933B2 (en) 2011-03-01 2016-01-26 Pharnext Compositions for treating amyotrophic lateral sclerosis
EP3108975A1 (en) * 2011-03-24 2016-12-28 Cornell University Aromatic-cationic peptides and uses of same
CN107496899A (zh) 2011-09-29 2017-12-22 梅约医学教育与研究基金会 芳族阳离子肽和使用它们的方法
CN107261380A (zh) 2011-10-17 2017-10-20 康奈尔大学 芳香族阳离子肽及其用途
US9675708B2 (en) * 2011-10-21 2017-06-13 Stemgenics, Inc. Functionalized nanoparticles for intracellular delivery of biologically active molecules
HK1204988A1 (en) 2012-02-22 2015-12-11 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
CA2865409C (en) * 2012-02-23 2020-07-21 Cornell University Aromatic-cationic peptides and uses of same
WO2014059029A1 (en) 2012-10-09 2014-04-17 President And Fellows Of Harvard College Treatment of age-related and mitochondrial diseases by inhibition of hif-1 alpha function
EP4397314B1 (en) 2012-10-22 2025-12-03 Stealth BioTherapeutics Inc. Treatment of left ventricular remodeling
US10793597B2 (en) 2013-03-01 2020-10-06 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial diseases associated with a mutation in SURF 1 or POLG gene resulting in a disruption of mitochondrial oxidative phosphorylation
EP3626252A1 (en) * 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
US10047395B2 (en) * 2013-06-26 2018-08-14 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions

Also Published As

Publication number Publication date
US12268724B2 (en) 2025-04-08
JP2022116008A (ja) 2022-08-09
US20260061023A1 (en) 2026-03-05
CN115990241A (zh) 2023-04-21
US11083772B2 (en) 2021-08-10
US11083771B2 (en) 2021-08-10
WO2014134554A1 (en) 2014-09-04
US20200345803A1 (en) 2020-11-05
CA2916880C (en) 2021-02-09
JP6918046B2 (ja) 2021-08-11
JP7072692B2 (ja) 2022-05-20
US20210401923A1 (en) 2021-12-30
US11771734B2 (en) 2023-10-03
HUE046924T2 (hu) 2020-03-30
CN115990242A (zh) 2023-04-21
JP7381652B2 (ja) 2023-11-15
US20240156892A1 (en) 2024-05-16
US20180147251A1 (en) 2018-05-31
JP2021098704A (ja) 2021-07-01
EP3626252A1 (en) 2020-03-25
JP2019147815A (ja) 2019-09-05
DK2961420T3 (da) 2019-10-07
JP2016511259A (ja) 2016-04-14
US20160228487A1 (en) 2016-08-11
ES2750258T3 (es) 2020-03-25
EP2961420A4 (en) 2016-08-17
EP2961420B1 (en) 2019-09-11
US9687519B2 (en) 2017-06-27
CN105407906A (zh) 2016-03-16
EP2961420A1 (en) 2016-01-06
CA2916880A1 (en) 2014-09-04

Similar Documents

Publication Publication Date Title
JP7381652B2 (ja) バース症候群の予防または治療のための方法及び組成物
US11266709B2 (en) Methods for the regulation of matrix metalloproteinase expression
EP2908839A2 (en) Methods for reducing risks associated with heart failure and factors associated therewith
US20200113966A1 (en) Methods and compositions for regulating srca2a expression levels in myocardial infarction
CN103933542A (zh) 预防和治疗烧伤损伤和继发性并发症的方法
WO2014185952A1 (en) Methods for the prevention or treatment of left ventricle remodeling
HK40019493A (en) Methods and compositions for the prevention or treatment of barth syndrome
HK1219673B (en) Methods and compositions for the prevention or treatment of barth syndrome
HK1219673A1 (en) Methods and compositions for the prevention or treatment of barth syndrome

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180322

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190322

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190419

R150 Certificate of patent or registration of utility model

Ref document number: 6518197

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250